The main reasons for the strong performance in the quarter are:
· Strong growth of haemophilia products reflecting continued patient growth but also advance purchases to secure access to treatment for a longer period than normal.
· An increased demand for Kineret as a result of the COVID-19 pandemic during the later part of the quarter. There is clinical interest in Kineret for the potential treatment of hyperinflammation related to COVID-19 disease.
· Favourable currency effects.
· Continued strong sales of Synagis based on underlying demand.
Guidance for the full-year 2020 of revenue in the range of
All figures in this press release are preliminary and unaudited.
Sobi will announce its Q1 2020 report on Wednesday
About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across
This information is information that
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 708 734 095
linda.holmstrom@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-sees-strong-revenue-and-ebita-growth-in-the-first-quarter-2020,c3086516
https://mb.cision.com/Main/14266/3086516/1228637.pdf
(c) 2020 Cision. All rights reserved., source